Experiment 69656
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Glycine max (FABACEAE) |
| Citation | KUMAR,NB: CANTOR,A: ALLEN,K: RICCARDI,D: BESTERMAN-DAHAN,K: SEIGNE,J: HELAL,M: SALUP,R: POW-SANG,J:. (2004). THE SPECIFIC ROLE OF ISOFLAVONES IN REDUCING PROSTATE CANCER RISK.. 59(2) |
| Amount utilized | |
| Compound isolated | |
| Disease | LARGER NUMBER OF SUBJECTS IN THE ISOFLAVONE SUPPLEMENTED GROUP THAN THE GROUP RECEIVING PLACEBO. INTERVENTION PERIOD. THESE DATA SUGGEST THAT SUPPLEMENTING EARLY STAGE PROSTATE CANCER PATIENTS WITH SOY ISOFLAVONES, EVEN IN A STUDY OF SHORT DURATION, ALTERED SURROGATE MARKERS OF PROLIFERATION SUCH AS SERUM PSA AND FREE TESTOSTERONE IN A UNCHANGED IN 69% OF THE SUBJECTS IN THE ISFLAVONE TREATED GROUP COMPARED TO 55% IN THE PLACEBO GROUP.HOWEVER WE DID NOT SEE AN INCREASE IN SHBG LEVELS.19% OF SUBJECTS RECEIVING SOY ISOFLAVONES REDUCED TOTAL PSA BY 2 POINTS OR MORE DURING THE POST INTERVENTION. 59 PATIENTS COMPLETED THE 12 WK INTERVENTION. SERUM FREE TESTOSTERONE WAS REDUCED OR SHOWED NO CHANGE IN 61% OF SUBJECTS IN THE ISFLAVONE GROUP COMPARED TO 33% IN THE PLACEBO GROUP. SERUM TOTAL PSA DECREASED OR WAS 76 ELIGIBLE PROSTATE CANCER PATIENTS WITH A GLEASON SCORE OF 6 OR BELOW, BETWEEN AGES 50 AND 80 WERE ADMITTED AND SUPPLEMENTED WITH SOY ISOFLAVONES OR PLACEBO FOR A 12 WK PERIOD AND CHANGES IN PSA AND STEROID HORMONES ANALYZED AT BASELINE AND TO EVALUATE THE EFFECTIVENESS OF SUPPLEMENTING A GROUP OF EARLY STAGE PROSTATE CANCER PATIENTS, WITH 60 MG OF SOY ISOFLAVONES IN PRODUCING A CHANGE IN HORMONAL AND PROLIFERATIVE RISK PARAMETERS THAT ARE IMPLICATED IN PROSTATE CANCER PROMOTION. |
| Dose amount | 60.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | ISOFLAVONE FRACTION |
| Gender | MALE |